|
|
|
|
ABI-007
A substance that is being studied in the treatment of cancer. It is a special form of the anticancer drug paclitaxel that may have fewer side effects and may be able to be given in higher doses. It belongs to the families of drugs called mitotic inhibitors and taxanes. (National Cancer Institute)
[an error occurred while processing this directive]
Additional Resources on ABI-007 from the National Cancer Institute
Cancer.gov Phase I/II Study of ABI-007 in Patients With Chemotherapy-Naïve Stage IV Non-Small
Cell Lung Cancer. Date First Published: 2004-01-23. BASIC STUDY INFORMATION. ...
Cancer.gov Phase II Study of ABI-007 in Patients With Inoperable Locally Recurrent or Metastatic
Melanoma. Date First Published: 2004-03-24. BASIC STUDY INFORMATION. ...
|
|
|